Search Results
Your search for Hope matches 3186 pages
Showing 551 - 600Patricia M. LoRusso, DO, PhD (hc), Elected 2023–2024 AACR President-Elect
The members of the American Association for Cancer Research (AACR) have elected Patricia M. LoRusso, DO, PhD (hc), as the President-Elect for the 2023 to 2024 term. Dr. LoRusso will become President-Elect on Monday, April 17, during the Annual Business Meeting of Members at the AACR Annual Meeting...
Nuances in Breast Cancer Imaging for Screening and Surveillance
Breast cancer screening and imaging-based surveillance after treatment remain suboptimal, largely because of confusion in the guidelines and the fact that dense breasts are too often ignored, according to Elizabeth Morris, MD, FACR, FSBI, FISMRM, Professor and Chair of the Department of Radiology...
Does Discrimination Accelerate Aging in Black Cancer Survivors?
Investigators have found that Black cancer survivors who reported high levels of discrimination showed greater biological aging and frailty than those who reported lower levels of discrimination, according to a new study published by Mandelblatt et al in the journal Cancer. Background...
Gut Microbiome May Influence How Patients With Non-Hodgkin Lymphoma Respond to CAR T-Cell Therapy
Researchers have revealed how microorganisms in the gut may influence the outcomes of patients with non-Hodgkin lymphoma undergoing chimeric antigen receptor (CAR) T-cell therapy, according to a study published by Stein-Thoeringer et al in Nature Medicine. Background Microorganisms live in or on...
Racial Inequalities in Prostate Cancer Care May Be Associated With Facility-Level Disparities
Racial minorities in the United States may be less likely to receive treatment for prostate cancer and, overall, have worse survival outcomes compared with individuals who are White, according to a new study published by Nguyen et al in Urologic Oncology. Typically, patient-level and...
New Research Highlights the Negative Impact of Continued Exclusion of Patients With African Ancestry From Research on Cancer Genomics
Researchers have revealed how the lack of genomic research for individuals with African ancestry—particularly those from the Sub-Saharan region—may be hampering efforts to reduce disparities for patients with prostate cancer, according to a new study published by Gheybi et al in JNCCN–Journal of...
Regorafenib, Ipilimumab, and Nivolumab in Microsatellite-Stable Metastatic Colorectal Cancer
In a single-institution phase I trial reported in JAMA Oncology, Marwan Fakih, MD, and colleagues found that the combination of regorafenib, ipilimumab, and nivolumab showed evidence of activity in patients with microsatellite-stable metastatic colorectal cancer who did not have liver metastases....
New Technique May Reduce Postoperative Complications in Prostate Cancer Surgery
Researchers have found that a novel technique used during prostate cancer surgery may reduce the risk of postoperative lymphocele by 50%, according to new findings presented by Neuberger et al at the 2023 European Association of Urology Annual Congress (Abstract A0656). The technique—involving the...
I’m Doing My Part to Erase the Stigma Surrounding Lung Cancer
Ironically, I received a diagnosis of lung cancer when I was feeling my healthiest. In December 2015, when I was just 51 years old, a routine chest x-ray found a small shadow on the lower lobe of my right lung. Despite being a never-smoker, a regular exerciser, and a healthy eater, my primary care...
Oncologists Applaud State of the Union’s Focus on Ending Cancer as We Know It
Julie R. Gralow, MD, FACP, FASCO, Chief Medical Officer and Executive Vice President of ASCO and the Association for Clinical Oncology, issued the following statement after President Joseph Biden’s State of the Union address on February 7. “ASCO applauds President Biden’s focus on ‘ending cancer as ...
‘Best of SABCS’: Top 7 Picks From the 2022 Meeting by Jame Abraham, MD, FACP
Among the high-quality abstract presentations at the San Antonio Breast Cancer Symposium (SABCS), a few always stand out as particularly meritorious. Each year, The ASCOPost asks our Associate Editor, breast cancer specialist Jame Abraham, MD, FACP, to give us his picks. Dr. Abraham is Chairman of ...
Extended Follow-up Supports First-Line Use of Nivolumab Plus Cabozantinib in Advanced Renal Cell Carcinoma
The 3-year follow-up of the phase III CheckMate 9ER trial demonstrates superior outcomes with the combination of nivolumab plus cabozantinib vs the former standard-of-care sunitinib as first-line treatment of advanced or metastatic renal cell carcinoma.1 These benefits were achieved with the...
Understanding the Link Between Prognostic Perception and Patient-Oncologist Prognostic Discordance in the Advanced Cancer Setting
Studies have shown that although patients with advanced cancer want their oncologists to give them an honest assessment of their prognosis, most patients still perceive their illness as curable.1 And that lack of understanding of their prognosis can lead to reduced use of hospice care and increased ...
Vitamin B5 May Help Improve Red Blood Cell Production in Patients With Myelodysplastic Syndromes
Researchers have discovered that vitamin B5 in combination with existing drugs may be the key to improving outcomes in patients with myelodysplastic syndromes (MDS) and ineffective red blood cell production, according to a novel study published by Mian et al in Science Translational Medicine....
Updates From City of Hope on Renal Cell, Prostate, and Urothelial Cancers
Sumanta K. Pal, MD, introduces his City of Hope colleagues, Hedyeh Ebrahimi, MD, MPH, who discusses the prevalence of dietary modification and supplement use in patients with metastatic renal cell carcinoma, and Daniela Castro, MSc, who discusses expanding eligibility criteria in kidney, prostate,...
Expert Point of View: Breelyn A. Wilky, MD
Discussant of the INTRIGUE abstract, Breelyn A. Wilky, MD, Director of Sarcoma Medical Oncology, Deputy Associate Director for Clinical Research, University of Colorado, Aurora, called the data presented “compelling evidence of the power of ctDNA [circulating tumor DNA] to identify predictive...
Estimating the Environmental Impact of Prostate Biopsies and MRIs May Help Reduce Health-Care Pollution
Investigators have estimated the environmental impacts of prostate magnetic resonance imaging (MRI) scans and prostate biopsies, according to a new study published by Michael S. Leapman, MD, MHS, and colleagues in European Urology. The findings suggest that more carefully selecting patients for...
Expert Point of View: Robert Rifkin, MD
Smoldering myeloma is an asymptomatic plasma cell disorder with a heterogeneous clinical behavior. Two trials presented at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition investigated early intervention for smoldering multiple myeloma, aiming for a “curative strategy”...
TALAPRO-2: Talazoparib Plus Enzalutamide Improves Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer
The TALAPRO-2 phase III clinical trial found that combining the poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib with the androgen receptor inhibitor enzalutamide resulted in significantly better progression-free survival vs the current standard of care for patients with metastatic...
Many Survivors of Childhood Hodgkin Lymphoma Show Signs of Neurocognitive Impairment
Long-term follow-up of survivors of childhood Hodgkin lymphoma from the St. Jude Lifetime Cohort showed signs of “epigenetic accelerated aging,” and many of these survivors had signs of neurocognitive impairment by their late 30s, researchers reported at the 2022 American Society of Hematology...
Expert Point of View: Alexey Danilov, MD, PhD
Alexey Danilov, MD, PhD, Co-Director, Toni Stephenson Lymphoma Center and Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California, commented on the phase III ALPINE trial comparing ibrutinib and zanubrutinib in patients...
Studies Explore Novel Triplet Combinations in AML
Two separate studies presented at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition provide preliminary evidence that triplet combinations may have a role in the treatment of acute myeloid leukemia (AML). Both triplets were based on the addition of a third drug to standard ...
Expert Point of View: Joseph C. Alvarnas, MD
“Pediatric acute lymphoblastic leukemia (ALL) is the paradigmatic success story in hematology,” said Joseph C. Alvarnas, MD, Professor in the Department of Hematology and Hematopoietic Cell Transplant, Vice President of Government Affairs, and Chief Clinical Advisor for AccessHope at City of Hope...
Is a Diet Higher in Plant-Based Foods Associated With a Lower Risk of Prostate Cancer Progression and Recurrence?
Patients with prostate cancer who reported the highest amounts of plant-based foods in their diets had a 52% lower risk of disease progression and a 53% lower risk of recurrence compared with those who had the lowest amounts of plants in their diets. The diet assessments were based on...
Pancreatic Cancer Rates May Be Rising Faster Among Younger Women Than Younger Men
Investigators have confirmed that rates of pancreatic cancer are rising overall, but they are rising faster among younger female patients—particularly among patients who identified as Black—than among male patients of the same age, according to a new study published by Abboud et al in...
Dietary Intervention May Help Reduce Chronic Fatigue, Improve Quality of Life for Cancer Survivors
Researchers have discovered that dietary interventions may help reduce fatigue, improve diet quality, and lead to an overall better quality of life for cancer survivors, according to a new study published by Weinhold et al in Nutrition and Cancer. Background For many cancer survivors, the side...
Is Efficacy of Sacituzumab Govitecan-hziy in the TROPiCS-02 Trial Dependent on Trop-2 Expression?
The latest analysis of the TROPiCS-02 breast cancer trial showed that the antibody-drug conjugate sacituzumab govitecan-hziy is effective in patients with a wide range of Trop-2 expression levels. The findings were reported at the 2022 San Antonio Breast Cancer Symposium by Hope S. Rugo, MD, FASCO, ...
Oncologists Applaud State of the Union’s Focus on Ending Cancer as We Know It
Julie R. Gralow, MD, FACP, FASCO, Chief Medical Officer and Executive Vice President of the American Society of Clinical Oncology and Association for Clinical Oncology, issued the following statement after President Joseph R. Biden’s State of the Union address earlier this week. “ASCO applauds...
Researchers Uncover Racial and Ethnic Disparities in Widely Used Precision Oncology Data Registry
Biorepositories created to support precision cancer research through their vast stores of genomic data may lack sufficient representation of cancer distribution among racial and ethnic minorities, according to a new study published by Cheung et al in npj Precision Oncology. The investigators also...
WHO Launches New Roadmap on Breast Cancer
The World Health Organization (WHO) has released a new Global Breast Cancer Initiative Framework, providing a roadmap to attain targets to save 2.5 million lives from breast cancer by 2040. The new framework recommends that countries implement three pillars of health promotion—early detection,...
FDA Approves Sacituzumab Govitecan-hziy for Pretreated Patients With HR-Positive, HER2-Negative Breast Cancer
On February 3, the U.S. Food and Drug Administration (FDA) approved sacituzumab govitecan-hziy (Trodelvy) for patients with unresectable, locally advanced or metastatic, hormone receptor (HR)-positive, HER2-negative (immunohistochemistry [IHC] 0, IHC 1+, or IHC 2+ with a negative in situ...
Researchers Develop AI Algorithm to Gain New Insights Into Glioblastoma
Researchers have developed an artificial intelligence (AI) algorithm, known as SPHINKS, capable of performing advanced computational analyses to identify potential therapeutic targets for patients with glioblastoma multiforme. The platform may also have applicability in other cancers, according to...
Immunotherapy Combined With Targeted Therapy in Patients With BRAF V600E–Mutated Colorectal Cancer
In one of the first clinical trials combining immunotherapy and targeted therapy for patients with BRAF V600E–mutated colorectal cancer, researchers discovered that a combination regimen of dabrafenib, trametinib, and spartalizumab resulted in long-lasting responses. The study findings published by ...
Risk of Subsequent Gastrointestinal Tract Malignancies After Blood or Marrow Transplantation
In a study reported in JAMA Oncology, McDonald et al found that receipt of blood or marrow transplantation (BMT) was associated with an increased risk of subsequent malignant neoplasms of the gastrointestinal (GI) tract. As stated by the investigators, “Survivors of BMT are at increased risk of...
New Analysis Sheds Light on Potential Link Between Ovulation and Ovarian Cancer
Individuals who ovulate for longer over their lifetimes may have a higher risk of developing ovarian cancer, suggesting that suppressing ovulation can lower this risk, according to a new study published by Fu et al in the Journal of the National Cancer Institute. The researchers also offered clues...
Receiving Chemotherapy in the Afternoon May Improve Treatment Outcomes in Some Patients With DLBCL
Utilizing chronochemotherapy—a method aimed at delivering chemotherapy at a time when the body is least vulnerable to its harmful effects and when the cancer cells are at their most vulnerable—may improve the outcomes of some patients with diffuse large B-cell lymphoma (DLBCL), according to a novel ...
Communicating Prognosis: A Core Competency of Patient-Centered Oncology Care
Most of us have felt our stomachs sink as we opened a patient’s radiology or laboratory report and realized the patient faced a grave situation. If we’re lucky, we have a couple of days before a scheduled patient appointment to prepare ourselves to deliver that bad news. Other times, we may have...
The Influence of Structural Racism and Poverty on Outcomes in Leukemia
In the United States, Black American patients with acute myeloid leukemia (AML) have notably worse survival outcomes compared to White patients. In addition, Black patients are less likely to receive intensive chemotherapy and undergo allogeneic stem cell transplants. Many researchers have reported ...
Many Survivors of Childhood Hodgkin Lymphoma Show Signs of Neurocognitive Impairment
Long-term follow-up of survivors of childhood Hodgkin lymphoma from the St. Jude Lifetime Cohort showed signs of “epigenetic accelerated aging,” and many of these survivors had signs of neurocognitive impairment by their late 30s, researchers reported at the 2022 American Society of Hematology...
Expert Point of View: Alexey Danilov, MD
Alexey Danilov, MD, PhD, Co-Director, Toni Stephenson Lymphoma Center and Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California, commented on the phase III ALPINE trial comparing ibrutinib and zanubrutinib in patients...
Studies Explore Novel Triplet Combinations in AML
Two separate studies presented at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition provide preliminary evidence that triplet combinations may have a role in the treatment of acute myeloid leukemia (AML). Both triplets were based on the addition of a third drug to standard ...
Palbociclib/Fulvestrant Does Not Improve Progression-Free Survival After Progression on a CDK4/6 Inhibitor in Metastatic Breast Cancer
The combination of palbociclib and fulvestrant did not prolong progression-free survival compared to fulvestrant alone in patients with hormone receptor–positive/HER2-negative metastatic breast cancer who had disease progression on prior treatment with a CDK4/6 inhibitor and endocrine therapy,...
Ensuring a More Diverse, Equitable, and Inclusive Workforce Within the SWOG Cancer Research Network
For more than 2 decades, Don S. Dizon, MD, FACP, FASCO, has devoted his medical career to the care of women’s cancers and the sexual health of cancer survivors of all genders and sexual identities. Early in his career, Dr. Dizon founded the Center for Sexuality, Intimacy, and Fertility at Women...
Expert Point of View: Joseph C. Alvarnas, MD
“Pediatric acute lymphoblastic leukemia (ALL) is the paradigmatic success story in hematology,” said Joseph C. Alvarnas, MD, Professor in the Department of Hematology and Hematopoietic Cell Transplant, Vice President of Government Affairs, and Chief Clinical Advisor for AccessHope at City of Hope...
Neoadjuvant Immunotherapy in Patients With Localized dMMR Colorectal Cancer
Investigators discovered that PD-1 inhibition prior to surgery may be effective for patients with localized mismatch repair–deficient or microsatellite instability–high (dMMR/MSI-H) colorectal cancer, according to a study published by Xiao et al in JNCCN–Journal of the National Comprehensive Cancer ...
Study Identifies Potential Molecular Differences Between Primary Breast Cancer and Its Metastases
Researchers have identified unique molecular features responsible for the development and progression of metastatic breast cancer, according to a novel study published by Garcia-Recio et al in Nature Cancer. They discovered that one of the key features involves changes in the immune system that are ...
Delaying Antibiotics May Not Affect Overall Survival Among Inpatients With Cancer Who Have Neutropenic Fever
Among inpatients with cancer who have neutropenic fever, delaying antibiotic treatment past 60 minutes from the time of fever detection may not reduce the short-term chance of overall survival, according to a new study published by Villars et al in the American Journal of Medical Quality....
Study Examines ‘Reconstructive Burnout’ Phenomenon: Patients Who Start Breast Reconstruction After Mastectomy but Don't Complete It
Nearly one-fourth of patients with breast cancer who start breast reconstruction after mastectomy don't complete the reconstructive process. The concept of reconstructive burnout was introduced and discussed in a study published by Halani et al in the January issue of Plastic and Reconstructive...
Uniting on Shared Priorities to Improve Cancer Care: ASCO and ECO Formalize Collaboration With a Memorandum of Understanding
ASCO and the European Cancer Organisation (ECO) are pleased to announce a new collaboration, formalized with a recently signed memorandum of understanding, that will advance their shared aims on cancer control. The two organizations will continue to work together to support the ECO-ASCO Special...
A Lifelong Love of Science Leads to a Leadership Role in Oncology for Laurie Glimcher, MD
For this installment of The ASCO Post’s Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with Laurie Glimcher, MD, President and Chief Executive Officer (CEO) of Dana-Farber Cancer Institute (DFCI). She is also Director of the Dana-Farber/Harvard Cancer Center, Principal...
